489 related articles for article (PubMed ID: 10178664)
1. An introduction to Markov modelling for economic evaluation.
Briggs A; Sculpher M
Pharmacoeconomics; 1998 Apr; 13(4):397-409. PubMed ID: 10178664
[TBL] [Abstract][Full Text] [Related]
2. Use of pharmacoeconomics in prescribing research. Part 5: modelling--beyond clinical trials.
Lang DL; Lopert R; Hill SR
J Clin Pharm Ther; 2003 Oct; 28(5):433-9. PubMed ID: 14632969
[TBL] [Abstract][Full Text] [Related]
3. Overview of pharmacoeconomic modelling methods.
Ademi Z; Kim H; Zomer E; Reid CM; Hollingsworth B; Liew D
Br J Clin Pharmacol; 2013 Apr; 75(4):944-50. PubMed ID: 22882459
[TBL] [Abstract][Full Text] [Related]
4. The incorporation of potential confounding variables in Markov models.
Nuijten MJ; Rutten F
Pharmacoeconomics; 2003; 21(13):941-50. PubMed ID: 12959626
[TBL] [Abstract][Full Text] [Related]
5. Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts.
Bala MV; Mauskopf JA
Pharmacoeconomics; 2006; 24(4):345-54. PubMed ID: 16605281
[TBL] [Abstract][Full Text] [Related]
6. Continuous-Time Semi-Markov Models in Health Economic Decision Making: An Illustrative Example in Heart Failure Disease Management.
Cao Q; Buskens E; Feenstra T; Jaarsma T; Hillege H; Postmus D
Med Decis Making; 2016 Jan; 36(1):59-71. PubMed ID: 26174352
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of uncertainty in health economic modelling studies.
O'Hagan A; McCabe C; Akehurst R; Brennan A; Briggs A; Claxton K; Fenwick E; Fryback D; Sculpher M; Spiegelhalter D; Willan A
Pharmacoeconomics; 2005; 23(6):529-36. PubMed ID: 15960550
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations.
Nuijten MJ
Pharmacoeconomics; 2004; 22(12):759-69. PubMed ID: 15294010
[TBL] [Abstract][Full Text] [Related]
9. Modelling in the economic evaluation of health care: selecting the appropriate approach.
Barton P; Bryan S; Robinson S
J Health Serv Res Policy; 2004 Apr; 9(2):110-8. PubMed ID: 15099459
[TBL] [Abstract][Full Text] [Related]
10. Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom.
Claxton L; Hodgson R; Taylor M; Malcolm B; Pulikottil Jacob R
Pharmacoeconomics; 2017 Feb; 35(2):237-248. PubMed ID: 27787744
[TBL] [Abstract][Full Text] [Related]
11. Interest of modelling in rheumatoid arthritis.
Beresniak A; Dupont DM; Becker JC; Merkesdal S
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S96-101. PubMed ID: 23078913
[TBL] [Abstract][Full Text] [Related]
12. Decision-analytical modelling in health-care economic evaluations.
Sun X; Faunce T
Eur J Health Econ; 2008 Nov; 9(4):313-23. PubMed ID: 17943332
[TBL] [Abstract][Full Text] [Related]
13. Principles of pharmacoeconomic analysis of drug therapy.
Freund DA; Dittus RS
Pharmacoeconomics; 1992 Jan; 1(1):20-31. PubMed ID: 10147037
[TBL] [Abstract][Full Text] [Related]
14. Selecting a decision model for economic evaluation: a case study and review.
Karnon J; Brown J
Health Care Manag Sci; 1998 Oct; 1(2):133-40. PubMed ID: 10916592
[TBL] [Abstract][Full Text] [Related]
15. Evaluation and review of pharmacoeconomic models.
Hay JW
Expert Opin Pharmacother; 2004 Sep; 5(9):1867-80. PubMed ID: 15330725
[TBL] [Abstract][Full Text] [Related]
16. Applied pharmacoeconomics: modeling data from internal and external sources.
Sanchez LA; Lee JT
Am J Health Syst Pharm; 2000 Jan; 57(2):146-55; quiz 155-6. PubMed ID: 10688243
[TBL] [Abstract][Full Text] [Related]
17. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression.
Zaric GS
Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544
[TBL] [Abstract][Full Text] [Related]
18. An introduction to the methods of decision-analytic modelling used in economic evaluations for Dermatologists.
McManus E; Sach TH; Levell NJ
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1829-1836. PubMed ID: 31127965
[TBL] [Abstract][Full Text] [Related]
19. A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process.
Li F; Jörg F; Li X; Feenstra T
Pharmacoeconomics; 2022 Nov; 40(11):1015-1032. PubMed ID: 36100825
[TBL] [Abstract][Full Text] [Related]
20. A mathematical approach for evaluating Markov models in continuous time without discrete-event simulation.
van Rosmalen J; Toy M; O'Mahony JF
Med Decis Making; 2013 Aug; 33(6):767-79. PubMed ID: 23715464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
